ANAPTYSBIO INC (ANAB) Stock Price & Overview
NASDAQ:ANAB • US0327241065
Current stock price
The current stock price of ANAB is 53.55 USD. Today ANAB is up by 3.34%. In the past month the price decreased by -15.03%. In the past year, price increased by 158.7%.
ANAB Key Statistics
- Market Cap
- 1.54B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.52
- Dividend Yield
- N/A
ANAB Stock Performance
ANAB Stock Chart
ANAB Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ANAB. When comparing the yearly performance of all stocks, ANAB is one of the better performing stocks in the market, outperforming 94.66% of all stocks.
ANAB Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ANAB. The financial health of ANAB is average, but there are quite some concerns on its profitability.
ANAB Earnings
On March 3, 2026 ANAB reported an EPS of 1.58 and a revenue of 108.25M. The company beat EPS expectations (65.04% surprise) and beat revenue expectations (15.29% surprise).
ANAB Forecast & Estimates
19 analysts have analysed ANAB and the average price target is 83.45 USD. This implies a price increase of 55.84% is expected in the next year compared to the current price of 53.55.
For the next year, analysts expect an EPS growth of -690.67% and a revenue growth -35.67% for ANAB
ANAB Groups
Sector & Classification
ANAB Financial Highlights
Over the last trailing twelve months ANAB reported a non-GAAP Earnings per Share(EPS) of -0.52. The EPS increased by 90.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.63% | ||
| ROE | -35.56% | ||
| Debt/Equity | 7.43 |
ANAB Ownership
ANAB Latest News, Press Relases and Analysis
ANAB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.52 | 354.636B | ||
| AMGN | AMGEN INC | 15.15 | 186.69B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 164.958B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.47 | 111.326B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.928B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.5 | 41.441B | ||
| INSM | INSMED INC | N/A | 31.186B | ||
| NTRA | NATERA INC | N/A | 29.449B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.041B | ||
| BIIB | BIOGEN INC | 11.79 | 27.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.65 | 25.171B | ||
| MRNA | MODERNA INC | N/A | 22.05B | ||
| INCY | INCYTE CORP | 12.5 | 19.252B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ANAB
Company Profile
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 104 full-time employees. The company went IPO on 2017-01-26. The firm is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. The company has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
Company Info
IPO: 2017-01-26
ANAPTYSBIO INC
10770 Wateridge Circle, Suite 210
San Diego CALIFORNIA 92121 US
CEO: Hamza Suria
Employees: 104
Phone: 18583626295
ANAPTYSBIO INC / ANAB FAQ
What does ANAB do?
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 104 full-time employees. The company went IPO on 2017-01-26. The firm is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. The company has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
Can you provide the latest stock price for ANAPTYSBIO INC?
The current stock price of ANAB is 53.55 USD. The price increased by 3.34% in the last trading session.
Does ANAPTYSBIO INC pay dividends?
ANAB does not pay a dividend.
How is the ChartMill rating for ANAPTYSBIO INC?
ANAB has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What sector and industry does ANAPTYSBIO INC belong to?
ANAPTYSBIO INC (ANAB) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for ANAB stock?
ANAPTYSBIO INC (ANAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.52).